Download PDF
CC BY-NC-ND 4.0 · Journal of Coloproctology 2023; 43(03): e166-e170
DOI: 10.1055/s-0043-1774725
Original Article

Study of Long Non-Coding RNA Tug1 Expression in Egyptian Colorectal Adenocarcinoma Patients

Yasmine Amin 
1   Medical Biochemistry Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Amel Ketat
1   Medical Biochemistry Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Hanan Kamal
1   Medical Biochemistry Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Inass Zaki
2   Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Ahmed Moaz
3   Colorectal Surgery Department, General Surgery Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Rasha Abdelmawla Ghazala
1   Medical Biochemistry Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
› Author Affiliations Funding The researchers did not receive any specific grant from funding agencies in the public or not for profit sections.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Purpose Colorectal cancer (CRC) is one of the most fatal tumors worldwide. In Egypt, most CRC cases occur in individuals > 40 years old. TUG1 has been proved to be disrupted in different malignancies and may have a critical role in tumor progression, invasion, and metastasis. However, its role in CRC has not been adequately studied.

Materials / Methods Quantitative real-time polymerase chain reaction (PCR) was used to evaluate the expression levels of long non-coding RNA (LncRNA) taurine upregulated gene 1 (TUG1), in nonmetastatic and metastatic CRC tissues and adjacent noncancerous tissues as control.

Results LncRNA TUG1 expression was significantly upregulated in both nonmetastatic and metastatic CRC tissues, in comparison with the adjacent noncancerous tissue. It was found that TUG1 could have a possible prognostic role in CRC, by comparing the sensitivity and specificity of TUG1 with those of CEA and CA19–9.

Conclusion The results of the current study suggest that the LncRNA TUG1 participates in the malignant behaviors of CRC cells.

Keywords

colorectal adenocarcinoma - CRC - LncRNA - TUG1 - PCR

Consent for Publication

Not applicable.


Availability of Data and Materials

The data supporting the conclusions are included within the article.


+ these authors contributed equally to the present work.




Publication History

Received: 14 April 2023

Accepted: 21 June 2023

Article published online:
21 September 2023

© 2023. Sociedade Brasileira de Coloproctologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Wang K, Ma W, Wu K. et al. Long-term colorectal cancer incidence and mortality after colonoscopy screening according to individuals' risk profiles. J Natl Cancer Inst 2021; 113 (09) 1177-1185
    CrossrefPubMedGoogle Scholar
  • 2 Setia A, Bhattacharya S, Agrawal A. lncRNA NLIPMT Inhibitors in Colorectal Cancer Management. In: Bhattacharya S, Page A, Maru S, Dawre S. (eds). Colorectal Cancer Diagnosis and Therapeutic Updates. New York: Bentham Book Publisher; 2022: 46-70
    Google Scholar
  • 3 Almeida-Lousada H, Mestre A, Ramalhete S. et al. Screening for Colorectal Cancer Leading into a New Decade: The “Roaring '20s” for Epigenetic Biomarkers?. Curr Oncol 2021; 28 (06) 4874-4893
    CrossrefPubMedGoogle Scholar
  • 4 Staller K, Olén O, Söderling J. et al. Chronic constipation as a risk factor for colorectal cancer: results from a nationwide, case-control study. Clin Gastroenterol Hepatol 2022; 20 (08) 1867-1876.e2
    CrossrefPubMedGoogle Scholar
  • 5 Aryee DNT, Fock V, Kapoor U, Radic-Sarikas B, Kovar H. Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis. Cells 2022; 11 (08) 1267
    CrossrefPubMedGoogle Scholar
  • 6 Hassani B, Mollanoori H, Pouresmaeili F, Asgari Y, Ghafouri-Fard S. Constructing mRNA, miRNA, circRNA and lncRNA regulatory network by Analysis of microarray data in breast cancer. Gene Rep 2022; 26: 101510
    CrossrefGoogle Scholar
  • 7 Zhang H, Yu L, Chen J. et al. Role of metabolic reprogramming of long non-coding rna in clear cell renal cell carcinoma. J Cancer 2022; 13 (02) 691-705
    CrossrefPubMedGoogle Scholar
  • 8 Tan J, Liu B, Zhou L. et al. LncRNA TUG1 promotes bladder cancer malignant behaviors by regulating the miR-320a/FOXQ1 axis. Cell Signal 2022; 91: 110216
    CrossrefPubMedGoogle Scholar
  • 9 Liu Q, Liu H, Cheng H, Li Y, Li X, Zhu C. Downregulation of long noncoding RNA TUG1 inhibits proliferation and induces apoptosis through the TUG1/miR-142/ZEB2 axis in bladder cancer cells. OncoTargets Ther 2017; 10: 2461-2471
    CrossrefPubMedGoogle Scholar
  • 10 He C, Liu Z, Jin L. et al. lncRNA TUG1-Mediated Mir-142-3p Downregulation Contributes to Metastasis and the Epithelial-to-Mesenchymal Transition of Hepatocellular Carcinoma by Targeting ZEB1. Cell Physiol Biochem 2018; 48 (05) 1928-1941
    CrossrefPubMedGoogle Scholar
  • 11 Li Y, Lv M, Song Z, Lou Z, Wang R, Zhuang M. Long non-coding RNA NNT-AS1 affects progression of breast cancer through miR-142-3p/ZEB1 axis. Biomed Pharmacother 2018; 103: 939-946
    CrossrefPubMedGoogle Scholar
  • 12 Zhang R, Huang XQ, Jiang YY, Li N, Wang J, Chen SY. LncRNA TUG1 regulates autophagy-mediated endothelial-mesenchymal transition of liver sinusoidal endothelial cells by sponging miR-142-3p. Am J Transl Res 2020; 12 (03) 758-772
    PubMedGoogle Scholar
  • 13 Rodrigo MC, Martin DS, Redetzke RA, Eyster KM. A method for the extraction of high-quality RNA and protein from single small samples of arteries and veins preserved in RNAlater. J Pharmacol Toxicol Methods 2002; 47 (02) 87-92
    CrossrefPubMedGoogle Scholar
  • 14 He N, Thippabhotla S, Zhong C. et al. Nano pom-poms prepared exosomes enable highly specific cancer biomarker detection. Commun Biol 2022; 5 (01) 660
    CrossrefPubMedGoogle Scholar
  • 15 Ibrahiem AT, Fawzy MS, Abu AlSel BT, Toraih EA. Prognostic value of BRAF/MIR-17 signature and B-Raf protein expression in patients with colorectal cancer: A pilot study. J Clin Lab Anal 2021; 35 (03) e23679
    CrossrefPubMedGoogle Scholar
  • 16 Yan Z, Bi M, Zhang Q, Song Y, Hong S. LncRNA TUG1 promotes the progression of colorectal cancer via the miR-138-5p/ZEB2 axis. Biosci Rep 2020; 40 (06) BSR20201025
    CrossrefPubMedGoogle Scholar
  • 17 Cuellar-Gómez H, Ocharán-Hernández ME, Calzada-Mendoza CC, Comoto-Santacruz DA. Association of Fusobacterium nucleatum infection and colorectal cancer: A Mexican study. Rev Gastroenterol Mex (Engl Ed) 2022; 87 (03) 277-284
    PubMedGoogle Scholar
  • 18 Kadja T, Liu C, Sun Y, Chodavarapu VP. Low-Cost, Real-Time Polymerase Chain Reaction System for Point-of-Care Medical Diagnosis. Sensors (Basel) 2022; 22 (06) 2320
    CrossrefPubMedGoogle Scholar
  • 19 Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 2021; 14 (10) 101174
    CrossrefPubMedGoogle Scholar
  • 20 Morris V, Kee B, Overman M. et al. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 2022; 13 (02) 647-656
    CrossrefPubMedGoogle Scholar
  • 21 He J, Wu W. Comprehensive landscape and future perspectives of long noncoding RNAs (lncRNAs) in colorectal cancer (CRC): Based on a bibliometric analysis. Noncoding RNA Res 2022; 8 (01) 33-52
    CrossrefPubMedGoogle Scholar
  • 22 Liu W, Meng J, Su R. et al. SP1-mediated up-regulation of lncRNA TUG1 underlines an oncogenic property in colorectal cancer. Cell Death Dis 2022; 13 (05) 433
    CrossrefPubMedGoogle Scholar
  • 23 Wang M, Hu H, Wang Y. et al. Long non-coding RNA TUG1 mediates 5-fluorouracil resistance by acting as a ceRNA of miR-197-3p in colorectal cancer. J Cancer 2019; 10 (19) 4603-4613
    CrossrefPubMedGoogle Scholar
  • 24 Shen X, Hu X, Mao J. et al. The long noncoding RNA TUG1 is required for TGF-β/TWIST1/EMT-mediated metastasis in colorectal cancer cells. Cell Death Dis 2020; 11 (01) 65
    CrossrefPubMedGoogle Scholar
  • 25 Jiang L, Zhou B, Fu D, Cheng B. lncRNA TUG1 promotes the development of oral squamous cell carcinoma by regulating the MAPK signaling pathway by sponging miR-593-3p. Cell Cycle 2022; 21 (17) 1856-1866
    CrossrefPubMedGoogle Scholar
  • 26 Farzaneh M, Najafi S, Anbiyaee O, Azizidoost S, Khoshnam SE. LncRNA MALAT1-related signaling pathways in osteosarcoma. Clin Transl Oncol 2023; 25 (01) 21-32
    CrossrefPubMedGoogle Scholar
  • 27 Tian L, Zhao ZF, Xie L, Zhu JP. Taurine up-regulated 1 accelerates tumorigenesis of colon cancer by regulating miR-26a-5p/MMP14/p38 MAPK/Hsp27 axis in vitro and in vivo. Life Sci 2019; 239: 117035
    CrossrefPubMedGoogle Scholar
  • 28 Barbagallo C, Brex D, Caponnetto A. et al. LncRNA UCA1, upregulated in CRC biopsies and downregulated in serum exosomes, controls mRNA expression by RNA-RNA interactions. Mol Ther Nucleic Acids 2018; 12: 229-241
    CrossrefPubMedGoogle Scholar